Live Breaking News & Updates on Phase 2 cerpass trial

Stay updated with breaking news from Phase 2 cerpass trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RP1 Plus Cemiplimab Misses Response End Points in Locally Advanced or Metastatic CSCC

The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, missing the primary end points of the phase 2 CERPASS trial.

Philip-astley-sparke , Replimune-group-inc , Replimune-group , Combination-of-rp1-and-cemiplimab- , Patients-with-locally-advanced-or-metastatic-cutaneous-squamous-cell-carcinoma , Phase-2-cerpass-trial ,